About Magid Abraham
Form D filings for Neurawell Therapeutics in 2024 list Magid Abraham as chief executive officer and director.
Magid Abraham first appears on SEC filings in 2024.
Experience
This experience comes from SEC filings. The years are when the filings name Magid Abraham in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Magid Abraham works with at each company, as listed on that company's latest Form D.
Neurawell Therapeutics, Inc. · Form D, Jun 10, 2024
JA
Jack Abraham
Director
TI
Tom Insel
Executive officer and director